DeutschNewstral
Article
Mmarketwatch.com on 2019-08-14 15:00
Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation
Related news
- MAkari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meetingmarketwatch.com
- MAkari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopanmarketwatch.com
- MMelinta Therapeutics' stock rockets on heavy volume after FDA accepts sNDA for Baxdelamarketwatch.com
Sapience Therapeutics ST-36 receives orphan drug designation from FDAwestfaironline.com
Penn spinout Linnaeus Therapeutics gets key FDA designationbizjournals.com- Imbrium Therapeutics receives FDA orphan drug designation for biliary tract cancer drugwestfaironline.com
- MNabriva Therapeutics' stock soars in heavy volume after FDA approves NDA for CABP treatmentmarketwatch.com
- MAgile Therapeutics' stock rockets nearly 4-fold after contraceptive patch Twirla gets favorable FDA committee nodmarketwatch.com
- DFDA fast-tracks Intensity Therapeutics’ breast cancer treatmentdailyvoiceplus.com
- Special FDA designation puts more wind behind BioCryst's sailsbizjournals.com
- MEDAP's stock rockets on heavy volume after prostate treatment gets FDA marketing clearancemarketwatch.com
- IGenprex up by 130% after receiving FDA fast track designationinvezz.com
- Portland biotech company gains FDA Fast Track designationbizjournals.com
- MAvinger's stock rockets on heavy volume after PAD treatment receives FDA clearancemarketwatch.com
FDA Approves Sage Therapeutics’ Zulressowsj.com- MHorizon Therapeutics halted for FDA advisory committee meeting on treatment for thyroid eye diseasemarketwatch.com
- Durham cancer drug developer sees shares pop 35% on FDA designationbizjournals.com
- HFDA grants Fast Track status to Juventas Therapeutics experimental heart failure drughome.crainscleveland.com
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK in Lupus Nephritisjdsupra.com- DFDA grants generic therapy designation for Purdue Pharma’s opioid overdose treatmentdailyvoiceplus.com